Hematopoietic stem cell transplantation does not increase the risk of infection-related complications for pediatric patients with Hodgkin and non-Hodgkin lymphomas: A multicenter nationwide study.
Adolescent
Bacterial Infections
/ epidemiology
Child
Child, Preschool
Disease-Free Survival
Drug Resistance, Multiple, Bacterial
Female
Hematopoietic Stem Cell Transplantation
Hodgkin Disease
/ complications
Humans
Infant
Invasive Fungal Infections
/ epidemiology
Lymphoma, Non-Hodgkin
/ complications
Male
Retrospective Studies
Risk Factors
Virus Diseases
/ epidemiology
Young Adult
children
epidemiology
hematopoietic stem cell transplantation
infection
lymphoma
multidrug resistance
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
24
06
2019
revised:
31
01
2020
accepted:
31
03
2020
pubmed:
15
4
2020
medline:
8
6
2021
entrez:
15
4
2020
Statut:
ppublish
Résumé
Hodgkin (HL) and non-Hodgkin lymphoma (NHL) represent a spectrum of lymphoid malignancies that are often curable with currently applied treatment regimens; however, 15%-30% of lymphoma patients still suffer from relapsed or refractory (rel/ref) disease. Although hematopoietic stem cell transplantation (HSCT) improves outcomes of second-line therapy for lymphoma in childhood, the complication rates in this group of patients, especially infectious complications (IC), remain unclear. The aim of this population-based cohort study was a retrospective analysis of incidence, epidemiology and profile of bacterial infections (BI), invasive fungal disease (IFD), and viral infections (VI) in primary or rel/ref lymphoma patients, both HL and NHL. We subdivided lymphoma patients into three groups: patients with primary conventional chemotherapy/radiotherapy regimens (group A), patients with rel/ref lymphoma treated with second-line chemotherapy (group B), and rel/ref lymphoma patients who underwent HSCT (group C). The medical records of the patients were biannually reported by each pediatric oncology center, and the data were analyzed centrally. Within 637 patients with primary lymphoma, at least one IC was diagnosed in 255 (40.0%), among 52 patients with rel/ref lymphoma 24 (46.2%) ICs were observed, and in transplanted group, 28 (57.1%) out of 49 children were diagnosed with IC (P = .151). The distribution of etiology of IC differed between the patient groups (A, B, C), with a predominance of BI in group A (85.6% vs 72.0% and 47.9%, respectively), VI in group C (9% and 16.0% vs 46.6%, respectively), and IFD in group B (5.4% vs 12.0% vs 5.5%, respectively). Overall, 500 (68.0%) episodes of bacterial IC were diagnosed in the entire group. Apart from HL patients treated with chemotherapy, in all the other subgroups of patients Gram-positives were predominant. The rate of multidrug-resistant bacteria was high, especially for Gram-negatives (41.1% in group A, 62.5% in group B, and 84.6% in group C). The infection-related mortality was comparable for each group. The incidence of IC was comparable during first- and second-line chemotherapy and after HSCT, but their profile was different for primary or re/ref lymphoma and depended on the type of therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Hodgkin (HL) and non-Hodgkin lymphoma (NHL) represent a spectrum of lymphoid malignancies that are often curable with currently applied treatment regimens; however, 15%-30% of lymphoma patients still suffer from relapsed or refractory (rel/ref) disease. Although hematopoietic stem cell transplantation (HSCT) improves outcomes of second-line therapy for lymphoma in childhood, the complication rates in this group of patients, especially infectious complications (IC), remain unclear.
OBJECTIVE
OBJECTIVE
The aim of this population-based cohort study was a retrospective analysis of incidence, epidemiology and profile of bacterial infections (BI), invasive fungal disease (IFD), and viral infections (VI) in primary or rel/ref lymphoma patients, both HL and NHL.
PATIENTS AND METHODS
METHODS
We subdivided lymphoma patients into three groups: patients with primary conventional chemotherapy/radiotherapy regimens (group A), patients with rel/ref lymphoma treated with second-line chemotherapy (group B), and rel/ref lymphoma patients who underwent HSCT (group C). The medical records of the patients were biannually reported by each pediatric oncology center, and the data were analyzed centrally.
RESULTS
RESULTS
Within 637 patients with primary lymphoma, at least one IC was diagnosed in 255 (40.0%), among 52 patients with rel/ref lymphoma 24 (46.2%) ICs were observed, and in transplanted group, 28 (57.1%) out of 49 children were diagnosed with IC (P = .151). The distribution of etiology of IC differed between the patient groups (A, B, C), with a predominance of BI in group A (85.6% vs 72.0% and 47.9%, respectively), VI in group C (9% and 16.0% vs 46.6%, respectively), and IFD in group B (5.4% vs 12.0% vs 5.5%, respectively). Overall, 500 (68.0%) episodes of bacterial IC were diagnosed in the entire group. Apart from HL patients treated with chemotherapy, in all the other subgroups of patients Gram-positives were predominant. The rate of multidrug-resistant bacteria was high, especially for Gram-negatives (41.1% in group A, 62.5% in group B, and 84.6% in group C). The infection-related mortality was comparable for each group.
CONCLUSIONS
CONCLUSIONS
The incidence of IC was comparable during first- and second-line chemotherapy and after HSCT, but their profile was different for primary or re/ref lymphoma and depended on the type of therapy.
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13292Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Lyman GH, Poniewierski MS, Culakova E. Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma. Expert Opin Drug Saf. 2016;15(4):483-492.
Zahid U, Akbar F, Amaraneni A, et al. A review of autologous stem cell transplantation in lymphoma. Curr Hematol Malig Rep. 2017;12(3):217-226.
Yıldız A, Öztürk HB, Albayrak M, et al. Is antimicrobial prophylaxis necessary for lymphoma patients? A single centre, real-life experience. J Oncol Pharm Pract. 2019;25(6):1381-1387.
Reiter A. Non-Hodgkin lymphoma in children and adolescents. Klin Padiatr. 2013;225(Suppl 1):S87-S93.
Minard-Colin V, Auperin A, Pillon M, Burke A, Anderson JR, Barkauskas DA. Results of the randomized Intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen. J Clin Oncol. 34(15 suppl) 10507-10507.
Reiter A. Euro-LB 02 treatment protocol for LBLs of the European Intergroup Cooperation on Childhood Non-Hodgkin Lymphoma International Multicentre Therapy Study Group. 2005.
Le Deley MC, Rosolen A, Williams DM et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol. 2010;28(25):3987-3993.
Körholz D. EuroNet-PHL-C1 study: First international Inter-Group Study for classical Hodgkin’s Lymphoma in Children and Adolescents. 2007.
Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Expert Rev Hematol. 2014;7(6):819-830.
Styczynski J, Gil L. Prevention of infectious complications in pediatric HSCT. Bone Marrow Transplant. 2008;42(Suppl 2):S77-S81.
De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus group. Clin Infect Dis. 2008;46:1813-1821.
Bassetti M, Righi E. Multidrug-resistant bacteria: what is the threat? Hematology Am Soc Hematol Educ Program. 2013;2013:428-432.
Zajac-Spychala O, Wachowiak J, Szmydki-Baran A, et al. Infectious complications in children treated for hodgkin and non-hodgkin lymphomas in polish pediatric leukemia/lymphoma study group: incidence, epidemiology and etiology. Leuk Lymphoma. 2019;60(1):124-132.
Inaba H, Pei D, Wolf J et al. Infection-related complications during treatment for childhood acute lymphoblastic leukemia. Ann Oncol. 2017;28(2):386-392.
Noga SJ, Choksi JK, Ding B, Dreiling L, Ozer H. Low incidence of neutropenic events in patients with lymphoma receiving first-cycle pegfilgrastim with chemotherapy: results from a prospective community-based study. Clin Lymphoma Myeloma. 2007;7(6):413-420.
Wolff DA, Crawford J, Dale DC, Poniewierski MS, Lyman GH. Risk of neutropenic complications based on a prospective nationwide registry of cancer patients initiating systematic chemotherapy. Proc Am Soc Clin Oncol. 2004;22(suppl 2):547.
Afzal S, Ethier MC, Dupuis LL, et al. Risk factors for infection-related outcomes during induction therapy for childhood acute lymphoblastic leukemia. Pediatr Infect Dis J. 2009;28(12):1064-1068.
Graubner UB, Porzig S, Jorch N et al. Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;50(2):259-263.
Salamonowicz M, Ociepa T, Frączkiewicz J, et al. Incidence, course, and outcome of Clostridium difficile infection in children with hematological malignancies or undergoing hematopoietic stem cell transplantation. Eur J Clin Microbiol Infect Dis. 2018;37(9):1805-1812.
Costa PO, Atta EH, Silva AR. Infection with multidrug-resistant gram-negative bacteria in a pediatric oncology intensive care unit: risk factors and outcomes. J Pediatr. 2015;91(5):435-441.
Kurosawa M, Yonezumi M, Hashino S, et al. Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol. 2012;96(6):748-757.